Download PDF
Arthritis und Rheuma 2022; 42(02): 100-105
DOI: 10.1055/a-1754-8854
Schwerpunkt

Reaktive Arthritis

Reactive Arthritis
Markus Rihl
1   Rheumatologische Facharztpraxis, Traunstein
,
Jens G. Kuipers
2   Rotes Kreuz Krankenhaus, Klinik für internistische Rheumatologie, Bremen
› Author Affiliations
› Further Information
    Permissions and Reprints

ZUSAMMENFASSUNG

Die reaktive Arthritis (ReA) ist definiert als sterile Gelenkentzündung, die innerhalb von Tagen bis Wochen nach einer extraartikulären bakteriellen Infektion (Primärinfektion) auftritt. Die häufigsten auslösenden Infektionen stellen eine Urethritis durch Chlamydia trachomatis bzw. eine Gastroenteritis durch Enterobakterien, seltener respiratorische Infekte, dar. Die Erreger oder Erregerbestandteile persistieren im Gelenk, sind aber im Gegensatz zur septisch-bakteriellen Arthritis nicht aus dem Gelenk anzüchtbar. Die typische artikuläre Manifestation der HLA-B27-assoziierten ReA, die zur Gruppe der Spondyloarthritiden (SpA) gezählt wird, ist die asymmetrische Oligoarthritis der unteren Extremität; seltener sind der Befall des Achsenskelettes oder extraartikuläre Manifestationen wie Enthesitis oder Iritis. Die Arthritis ist zu Beginn oft sehr schmerzhaft und hochentzündlich und zumeist selbstlimitierend. Chronische Verläufe, die nicht ausreichend auf symptomatische Therapie ansprechen, treten in bis zu 30 % der Patienten auf; für diese Formen sind immunmodulierende Therapien reserviert. Eine zunehmende Zahl von Fallbeschreibungen und kleineren, prospektiven Untersuchungen zeigen eine sehr gute Wirksamkeit von Biologika wie TNF-α-, IL6- und IL17-Inhibitoren.

ABSTRACT

Reactive arthritis (ReA) is defined as a sterile joint inflammation following an extra-articular infection (primary infection) mostly caused by Chlamydia trachomatis (urethritis) or enterobacter species (gastroenteritis). A pivotal phenomenon of ReA is the presence of non-culturable bacteria or fragments thereof persisting in the joint in contrast to septic arthritis, where the causing bacteria can be cultivated from the affected joint. The HLA-B27 associated form of ReA is defined as part of the spondyloarthritis (SpA) group and characterized by a mostly self-limiting oligoarthritis of the lower limbs, very often with acute and highly inflammatory onset. Up to 30 % of patients develop chronic symptoms not responding sufficiently to symptomatic treatment. These patients are treated with immunomodulatory agents. An increasing number of case reports or small prospective studies show very good efficacy of biologics such as TNFα-, IL6- und IL17-inhibitors.

Schlüsselwörter

Reaktive Arthritis - Spondyloarthritis - Primärinfektion - Chlamydia trachomatis - Persistenz

Keywords

Reactive arthritis - spondyloarthritis - primary infection - Chlamydia trachomatis - persistence


Publication History

Article published online:
19 April 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Reiter H. Über eine bisher unbekannte Spirochäteninfektion (Spirochaetosis arthritica).. Deutsche Medizinische Wochenschrift 1916; 42: 1535-1536
    Article in Thieme ConnectGoogle Scholar
  • 2 Ahvonen P, Sievers K, Aho K. Arthritis associated with Yersinia enterocolitica infection. Acta Rheumatol.. Scand. 1969; 15: 232-253
    Google Scholar
  • 3 Aho K, Ahvonen P, Lassus A. et al HL-A antigen 27 and reactive arthritis.. Lancet 1973; 02: 157-161
    CrossrefPubMedGoogle Scholar
  • 4 Yu D, Kuipers JG. Role of bacteria and HLA-B27 in the pathogenesis of reactive arthritis.. Rheum Dis Clin North Am 2003; 29: 21-36
    CrossrefPubMedGoogle Scholar
  • 5 Braun J, Kingsley G, van der Heijde D. et al On the difficulties of establishing a consensus on the definition of and diagnostic investigations for reactive arthritis. Results and discussion of a questionnaire prepared for the 4th International Workshop on reactive arthritis. Berlin, Germany, July 3–6, 1999.. The Journal of Rheumatology 2000; 27 (09) 2185-2192
    PubMedGoogle Scholar
  • 6 Rudwaleit M, van der Heijde D, Landewé R. et al The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general.. Ann Rheum Dis 2011; 70: 25-31
    CrossrefPubMedGoogle Scholar
  • 7 Horton DB, Strom BL, Putt ME. et al Epidemiology of Clostridium difficile Infection-associated reactive arthritis in children: an underdiagnosed, potentially morbid condition.. JAMA Pediatr 2016; 05: 170
    Google Scholar
  • 8 Lahu A, Backa T, Ismaili J. et al Modes of presentation of reactive arthritis based on the affected joints.. Med Arch 2015; 69: 42-45
    CrossrefPubMedGoogle Scholar
  • 9 Kvien TK, Glennas A, Melby G. et al Reactive arthritis: incidence, triggering agents and clinical presentation.. J Rheumatol 1994; 21: 115-122
    Google Scholar
  • 10 Denison H, Curtis EM, Clynes MA. The incidence of sexually acquired reactive arthritis: a systematic literature review.. Clinical Rheumatology 2016; 35: 2639-2648
    CrossrefPubMedGoogle Scholar
  • 11 Owlia MB, Eley AR. Is the role of Chlamydia trachomatis underestimated in patients with suspected reactive arthritis?. Int J Rheum Dis 2010; 13: 27-38
    CrossrefPubMedGoogle Scholar
  • 12 Toivanen A, Toivanen P. Reactive arthritis.. Best Practice & Research Clinical Rheumatology 2004; 18: 689-703
    CrossrefPubMedGoogle Scholar
  • 13 Keithlin J, Sargeant J, Thomas MK. et al Systematic review and meta-analysis of the proportion of Campylobacter cases that develop chronic sequelae.. BMC Public Health 2014; 14: 1203
    CrossrefPubMedGoogle Scholar
  • 14 Lories RJ, McInnes IB.. Primed for inflammation: enthesis-resident T cells Nature Medicine. 2012; 18: 1018-1019
    PubMedGoogle Scholar
  • 15 Romand X, Liu X, Rahman MA. et al Mediation of Interleukin-23 and Tumor Necrosis Factor-driven reactive arthritis by Chlamydia-infected macrophages in SKG mice.. Arthritis Rheumatol 2021; 73: 1200-1210
    CrossrefPubMedGoogle Scholar
  • 16 Carter JD. Reactive arthritis: defined etiologies, emerging pathophysiology, and unresolved treatment. Infect.. Disease Clin 2009; 20: 827-847
    Google Scholar
  • 17 Kaarela K, Jäntti JK, Kotaniemi KM. Similarity between chronic reactive arthritis and ankylosing spondylitis. A 32–35-year follow-up study.. Clin Exp Rheumatol 2009; 27: 325-328
    PubMedGoogle Scholar
  • 18 Rihl M, Klos A, Köhler L. et al Infection and musculoskeletal conditions: Reactive arthritis.. Best Pract Res Clin Rheumatol 2006; 20: 1119-1137
    CrossrefPubMedGoogle Scholar
  • 19 Haibel H, Rudwaleit M, Sieper J. et al Diagnostik der reaktiven Arthritis. Z.. Rheumatol 2004; 63: 211-215
    Google Scholar
  • 20 Brzank M, Wollenhaupt J. Infection-induced reactive arthritis: etiopathogenesis, clinical spectrum, therapy.. Z Rheumatol 2013; 72: 977-985
    CrossrefPubMedGoogle Scholar
  • 21 Pignanelli S, Shurdhi A, Delucca F. Simultaneous use of direct and indirect diagnostic techniques in atypical respiratory infections from Chlamydophila pneumoniae and Mycoplasma pneumoniae.. J Clin Lab Ana 2009; 23: 206-209
    CrossrefPubMedGoogle Scholar
  • 22 Bardin T, Enel C, Cornelis F. et al Antibiotic treatment of veneraeal disease and Reiter´s syndrome in a Greenland population.. Arthritis Rheum 1992; 35: 190-194
    CrossrefPubMedGoogle Scholar
  • 23 Adimora AA. Treatment of uncomplicated genital Chlamydia trachomatis infection in adults.. Clin Infect Dis 2002; 35: 183-186
    CrossrefPubMedGoogle Scholar
  • 24 Barber CE, Kim J, Inman RD. et al Antibiotics for treatment of reactive arthritis: a systematic review and meta-analysis.. J Rheumatol 2013; 40: 916-928
    CrossrefPubMedGoogle Scholar
  • 25 Carter JD, Espinoza LR, Inman RD. et al Combination antibiotics as a treatment for chronic Chlamydia-induced reactive arthritis: a double-blind, placebo-controlled, prospective trial.. Arthritis Rheum 2010; 62: 1298-1307
    CrossrefPubMedGoogle Scholar
  • 26 Köhler L, Kuipers JG, Zeidler H. Managing seronegative spondarthritides.. Rheumatology 2000; 39: 360-368
    CrossrefPubMedGoogle Scholar
  • 27 Reveille JD, Arnett C. Spondyloarthritis: update on pathogensis and management.. Am J Med 2005; 118: 592-603
    CrossrefPubMedGoogle Scholar
  • 28 Anandarajah A, Ritchlin CT. Treatment update on spondyloarthropathy.. Curr Op Rheumatol 2005; 17: 247-256
    CrossrefPubMedGoogle Scholar
  • 29 Rudwaleit M, Braun J, Sieper J. Treatment of reactive arthritis: a practical guide.. BioDrugs 2000; 13: 21-28
    CrossrefPubMedGoogle Scholar
  • 30 Zeng H, Luo B, Zhang Y. et al Treatment of reactive arthritis with biological agents: a review.. Biosci Rep 2020; 40: BSR20191927
    CrossrefPubMedGoogle Scholar
  • 31 Morris D, Inman RD. Reactive arthritis: developments and challenges in diagnosis and treatment.. Curr Rheumatol Rep 2012; 14: 390-394
    CrossrefPubMedGoogle Scholar
  • 32 Tanaka T, Kuwahara Y, Shima Y. et al Successful treatment of reactive arthritis with a humanized anti-interleukin-6 receptor antibody, tocilizumab.. Arthritis Rheum 2009; 61: 1762-1764
    CrossrefPubMedGoogle Scholar
  • 33 Kwan K, Bharadwaj S, Inderjeeth C. Response to treatment with tocilizumab of reactive arthritis induced by intravesical bacillus Galmette-Guérin unresponsive to DMARDs.. Int J Rheum Dis 2012; 15: 73-75
    CrossrefPubMedGoogle Scholar
  • 34 Padhan P, Maikap D. Secukinumab therapy in reactive arthritis: Report of two cases.. Mod Rheumatol Case Rep 2022; 06: 22-24
    CrossrefPubMedGoogle Scholar
  • 35 Van Mens LJ, van de Sande MG, Menegatti S. et al Interleukin-17 blockade with secukinumab in peripheral spondyloarthritis impacts synovial immunopathology without compromising systemic immune responses.. Arthritis Rheumatol 2018; 70 1994–2002sci Rep. 2020;40 BSR20191927
    CrossrefPubMedGoogle Scholar